GLP-1 Market
LLY $1166.51 ▼ -1.4% NVO $38.06 ▼ -1.3% PFE $28.37 ▼ -0.1% VKTX $26.65 ▼ -6.0% KLRA $10.77 ▼ -4.9% GPCR $22.31 ▼ -6.7% RHHBY $53.77 ▼ -0.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Trijardy® XR

Company
Humanis Saglık Anonim Sirketi
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 14, 2026

Trial details
  • Completed NCT NCT03259490

    This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

    Not yet reported Boehringer Ingelheim 30 participants Est. completion 2017-11-13 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03629054

    This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

    Not yet reported Boehringer Ingelheim 30 participants Est. completion 2018-11-05 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT07213895

    Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

    Not yet reported Humanis Saglık Anonim Sirketi 14 participants Est. completion 2025-09-18 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07691203

    Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

    Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2026-07-01 1 site Stand-alone
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT07872358

    Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

    Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2026-10-07 1 site Stand-alone
    Type 2 diabetesCardiovascular disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Trijardy® XR, Trijardy® XR Tablets

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.